OS Therapies Incorporated (OSTX) News
Track canonical SquawkNews coverage tagged to OSTX, OS Therapies Incorporated. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 13 indexed stories across 9 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
OS Therapies, Inc. (OSTX) WHO Clears 'Herlystic'; UK Filing Next, Orbis Path Planned
OS Therapies received WHO approval of 'Herlystic' for OST-HER2 and plans to file first with the U.K. MHRA under Project Orbis, followed by FDA, EMA and TGA. FDA BLA is targeted under Accelerated Approval after final 3-ye
REGULATION | Sep 24, 2026, 12:23 PM UTC
L
OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac)
New York, New York and Rockville, Maryland--(. - September 24, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, t
NEWS | Sep 24, 2026, 12:22 PM UTC
L
OS Therapies achieves incremental FDA alignment for OST-HER2
OS Therapies says it has achieved incremental alignment with the FDA and accepted an MHRA Project Orbis invitation for its OST-HER2 metastatic osteosarcoma program.
REGULATION | Sep 17, 2026, 10:01 AM UTC
L
OS Therapies, Inc. (AMEX:OSTX) Aligned With MHRA/EMA on CMAA; Phase 3 To Start in Q4 2026
OS Therapies achieved full alignment with the UK MHRA and EU EMA on its Conditional Marketing Authorisation plans and Phase 3 design for OST-HER2, expects CMAA filing in coming weeks, and intends to start the confirmator
NEWS | Sep 15, 2026, 11:53 AM UTC
L
OS Therapies Announces Full Alignment with UK MHRA and EU EMA for Conditional Marketing Authorisation Application Filing
New York, New York and Rockville, Maryland--(. - September 15, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, t
NEWS | Sep 15, 2026, 11:51 AM UTC
M
OS Therapies reports statistically significant interim 3-year OS benefit
OS Therapies (OSTX) announced a statistically significant benefit for OST-HER2-treated patients in interim 3-year overall survival analysis from its Phase 2b pulmonary metastatic osteosarcoma trial.
EQUITY | Sep 08, 2026, 10:06 AM UTC
L
OS Therapies updates OST-HER2 metastatic osteosarcoma program
OS Therapies, Inc. said it provided an update on its OST-HER2 metastatic osteosarcoma program and announced upcoming conference attendance by its management team and business development advisors.
EQUITY | Sep 02, 2026, 11:26 AM UTC
M
OS Therapies reports Q2 2026 financials; shares business and regulatory updates
OS Therapies (OSTX) reports its second-quarter 2026 financials and provides accompanying business and regulatory updates.
REGULATION | Aug 17, 2026, 11:50 AM UTC
L
OS Therapies Expects Phase 3 Study For The OST-HER2 Metastatic Osteosarcoma Program To Begin Near End Of Q3 2026
OS Therapies, Inc. (NYSE: OSTX ) ("OS Therapies" or "the Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today provides a third quarter 2026 corporate outlook. The outlook focuses on up
FX | Jul 06, 2026, 01:10 PM UTC
L
OS Therapies Third Quarter 2026 Corporate Outlook
Upcoming Type B Statistical Methods Meeting expected to set stage for FDA to align with EMA and MHRA on use of Fall 2026 3-year overall survival data combined with biomarkers to support early market access
REGULATION | Jul 06, 2026, 01:01 PM UTC
H
OS Therapies shares are trading lower. The company requested a Type B Meeting to follow up on FDA guidance for its OST‑HER2 BLA, submitted b
OS Therapies shares are trading lower. The company requested a Type B Meeting to follow up on FDA guidance for its OST‑HER2 BLA, submitted biomarker data to the BEST program, added a synthetic control arm, and sought Rol
EARNINGS | Jun 30, 2026, 05:58 PM UTC
H
OS Therapies Requests FDA Type B Meeting To Review Its 2.5-Year OST-HER2 Overall Survival Data And To Confirm Alignment That 3-year Overall
OS Therapies, Inc. (NYSE: OSTX ) ("OS Therapies" or "the Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today provided regulatory update on the Company's interactions with the U.S. Foo
EARNINGS | Jun 30, 2026, 11:45 AM UTC
L
OSTX Publishes Clinical Trial Data
OSTX OS Animal Health announces peer-reviewed publication of clinical trial data for OST-HER2 plus palliative radiation as frontline treatment in canine osteosarcoma
EQUITY | Jun 26, 2026, 11:47 AM UTC